{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:03:50Z","timestamp":1782126230722,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Cyberonics"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck and Company"},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca Pharmaceuticals"},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014934","name":"Avanir Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014934","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb Company"},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014478","name":"Forest Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014478","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001462","name":"American Psychiatric Publishing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jad.2018.12.074","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T20:15:32Z","timestamp":1545682532000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder"],"prefix":"10.1016","volume":"246","author":[{"given":"Farnaz","family":"Hooshmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2563-6916","authenticated-orcid":false,"given":"Dennis","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell'Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-0661","authenticated-orcid":false,"given":"Po W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5132-453X","authenticated-orcid":false,"given":"Terence A.","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2018.12.074_bib0001","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1176\/appi.ajp.160.7.1252","article-title":"Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up","volume":"160","author":"Altshuler","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1176\/appi.ajp.2016.15040558","article-title":"Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison","volume":"174","author":"Altshuler","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2015.05.070","article-title":"Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study","volume":"185","author":"Amsterdam","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.12.074_bib0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ps.2007.58.1.85","article-title":"Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders","volume":"58","author":"Baldessarini","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"Suppl 2","key":"10.1016\/j.jad.2018.12.074_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-5618.2012.00991.x","article-title":"Treatment options for acute depression in bipolar disorder","volume":"14","author":"Bauer","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.12.074_bib0032","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4088\/JCP.v69n1009","article-title":"Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis","volume":"69","author":"Bond","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0033","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","article-title":"Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression","volume":"60","author":"Calabrese","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0006","series-title":"User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version","author":"First","year":"1997"},{"key":"10.1016\/j.jad.2018.12.074_bib0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1176\/appi.ajp.2008.08030322","article-title":"Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression","volume":"166","author":"Frye","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0447.2008.01257.x","article-title":"Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks","volume":"118","author":"Ghaemi","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2018.12.074_bib0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0004867412441103","article-title":"Antidepressants: the scapegoat of poor outcome bipolar disorder?","volume":"46","author":"Goldberg","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0011","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1176\/appi.ajp.2007.05122032","article-title":"Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD","volume":"164","author":"Goldberg","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0012","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.4088\/JCP.v69n1014","article-title":"International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression","volume":"69","author":"Kasper","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0013","series-title":"Advances in the Treatment of Bipolar Disorder","author":"Ketter","year":"2015"},{"key":"10.1016\/j.jad.2018.12.074_bib0014","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0447.2008.01237.x","article-title":"Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration","volume":"118","author":"Licht","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2018.12.074_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jad.2017.07.023","article-title":"Efficacy and safety of long-term antidepressant treatment for bipolar disorders - a meta-analysis of randomized controlled trials","volume":"223","author":"Liu","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.12.074_bib0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","article-title":"A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)","volume":"71","author":"McElroy","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2018.12.074_bib0017","first-page":"4","article-title":"A review of FDA-approved treatment options in bipolar depression","volume":"18","author":"McIntyre","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2018.12.074_bib0034","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.bp.104.007773","article-title":"Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders","volume":"189","author":"Otto","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0018","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0036","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1034\/j.1399-5618.2001.30505.x","article-title":"Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers","volume":"3","author":"Post","year":"2001","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jad.2018.12.074_bib0019","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1001\/archpsyc.1983.01790220086014","article-title":"Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination","volume":"41","author":"Prien","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1399-5618.2002.01195.x","article-title":"A clinical monitoring form for mood disorders","volume":"4","author":"Sachs","year":"2002","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.12.074_bib0021","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa064135","article-title":"Effectiveness of adjunctive antidepressant treatment for bipolar depression","volume":"356","author":"Sachs","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2018.12.074_bib0022","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(03)00165-3","article-title":"Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)","volume":"53","author":"Sachs","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jad.2017.05.007","article-title":"Lifetime anxiety disorder and current anxiety symptoms associated with hastened depressive recurrence in bipolar disorder","volume":"219","author":"Shah","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jad.2018.12.074_bib0023","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4088\/JCP.09r05385gre","article-title":"Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis","volume":"72","author":"Sidor","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2018.12.074_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpsychires.2015.06.015","article-title":"Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data","volume":"68","author":"Tada","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2018.12.074_bib0027","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0028","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archpsyc.1990.01810240026005","article-title":"Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis","volume":"47","author":"Tohen","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0029","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4088\/JCP.v68n1002","article-title":"Self-reported history of manic\/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"68","author":"Truman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0038","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.euroneuro.2015.07.013","article-title":"Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials","volume":"25","author":"Vazquez","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2018.12.074_bib0030","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1017\/S1461145713000023","article-title":"Overview of antidepressant treatment of bipolar depression","volume":"16","author":"Vazquez","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.12.074_bib0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eurpsy.2004.12.002","article-title":"The treatment of mixed states and the risk of switching to depression","volume":"20","author":"Vieta","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.074_bib0039","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4088\/JCP.v63n0607","article-title":"A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers","volume":"63","author":"Vieta","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718318020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718318020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:33:40Z","timestamp":1759023220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718318020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"alternative-id":["S0165032718318020"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.12.074","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.12.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}